Autolus Therapeutics (AUTL) AI Stock Analysis

• Market Cap: $364.61M
• Dividend Yield: N/A
• Average Volume (3M): 3.28M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: 407.86%
• EPS Growth: 30.14%
• Country: US
• Employees: 647
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.30
• Shares Outstanding: 266,143,280
• 10 Day Avg. Volume: 5,458,689
• 30 Day Avg. Volume: 3,284,650
• PEG Ratio: 0.10
• Price to Book (P/B): 1.40
• Price to Sales (P/S): 59.25
• P/FCF Ratio: -2.49
• Enterprise Value/Market Cap: 1.07
• Enterprise Value/Revenue: 7.63
• Enterprise Value/Gross Profit: -2.47
• Enterprise Value/Ebitda: -1.55
• 1Y Price Target: $7.68
• Price Target Upside: 460.58% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -0.92
• Revenue Forecast (FY): $72.26M

• Rating: 47 Neutral
• Price Target: $1.50 ▲(9.49% Upside)

Autolus Therapeutics faces significant financial challenges with ongoing losses and negative cash flows, impacting its overall score. While technical indicators suggest a bearish trend, the company has shown strong market penetration and is well-capitalized, providing some support for future growth.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong demand for Autolus' products, suggesting successful market penetration and potential for future expansion.

Regulatory Approval

Regulatory approval by NICE enhances market access and credibility, potentially increasing sales and supporting long-term growth in the UK market.

Market Penetration

Increased market share in CAR T therapy indicates strong competitive positioning and potential for sustained growth as the company expands its reach.

Negative Factors

Operational Losses

Continued operational losses highlight challenges in achieving profitability, which could strain resources and impact long-term financial stability.

High Cost of Sales

High cost of sales relative to revenue suggests inefficiencies that may hinder margin improvement and profitability over time.

Negative Cash Flow

Negative cash flow indicates reliance on external funding, which may not be sustainable long-term, potentially affecting operational flexibility.

Autolus Therapeutics Business Overview & Revenue Model

Company Description

Autolus Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation T cell therapies for the treatment of cancer. The company specializes in engineered T cell therapies, leveraging its proprietary technology platforms to create innovative products aimed at addressing significant unmet medical needs in oncology. Autolus is dedicated to advancing its pipeline of product candidates through clinical trials, primarily targeting hematological malignancies and solid tumors.

How the Company Makes Money

Autolus Therapeutics generates revenue primarily through strategic partnerships and collaborations with larger pharmaceutical companies, which provide funding for research and development activities in exchange for rights to commercialize products developed from Autolus' technology. Additionally, the company may receive milestone payments as its product candidates progress through clinical trials and regulatory approvals. While Autolus is primarily in the development phase and may not yet have substantial product sales, revenue can also be derived from licensing agreements and grants to support its ongoing research initiatives.

Autolus Therapeutics Financial Statement Overview

Summary

Autolus Therapeutics shows strong revenue growth but struggles with profitability and cash flow. The balance sheet is solid with low leverage and substantial cash reserves, yet operational losses and negative cash flows are significant challenges.

Income Statement

Autolus Therapeutics has shown significant revenue growth in recent years, with a notable increase from $1.7M in 2023 to $10.1M in 2024. However, the company continues to report negative gross and net profit margins, indicating ongoing challenges in achieving profitability. The EBIT and EBITDA margins are also negative, reflecting substantial operational losses.

Balance Sheet

The company's balance sheet highlights a strong equity position, with a substantial cash reserve relative to its liabilities. The debt-to-equity ratio is low at 0.12, suggesting limited leverage, but the company has consistently negative net income affecting ROE, which remains negative. The equity ratio is relatively stable, indicating a solid asset structure.

Cash Flow

Autolus Therapeutics is facing challenges with negative free cash flow, which has worsened in recent periods. Although operating cash flow is negative, it is supported by financing activities, indicating reliance on external funding. The free cash flow to net income ratio is unfavorable, reflecting difficulties in converting income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	51.13M	10.12M	1.70M	6.19M	1.51M	1.72M
Gross Profit	-158.22M	-130.90M	1.70M	6.19M	1.51M	-133.17M
EBITDA	-250.91M	-233.07M	-156.77M	-132.24M	-132.47M	-162.58M
Net Income	-224.80M	-220.66M	-208.38M	-148.84M	-142.10M	-142.09M
Balance Sheet
Total Assets	661.95M	782.73M	375.38M	490.27M	405.56M	294.24M
Cash, Cash Equivalents and Short-Term Investments	367.41M	588.02M	239.57M	382.44M	310.34M	154.09M
Total Debt	65.83M	52.63M	52.97M	24.26M	68.01M	54.16M
Total Liabilities	396.50M	355.40M	263.91M	191.60M	92.24M	84.20M
Stockholders Equity	265.45M	427.32M	111.47M	298.67M	313.32M	210.03M
Cash Flow
Free Cash Flow	-278.04M	-241.09M	-156.57M	-123.15M	-126.72M	-132.44M
Operating Cash Flow	-254.18M	-206.27M	-145.59M	-112.31M	-117.86M	-117.76M
Investing Cash Flow	-311.67M	-394.55M	-10.99M	-10.84M	-8.86M	-14.68M
Financing Cash Flow	27.46M	589.55M	-883.00K	223.61M	284.06M	74.42M

Autolus Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.37
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUTL, the sentiment is Positive. The current price of 1.37 is above the 20-day moving average (MA) of 1.36, below the 50-day MA of 1.49, and below the 200-day MA of 1.75, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 48.26 is Neutral, neither overbought nor oversold. The STOCH value of 48.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AUTL.

Autolus Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LRMR	49 Neutral	$314.12M	―	-78.24%	―	―	-67.41%
AUTL	47 Neutral	$364.61M	―	-60.52%	―	407.86%	30.14%
BNTC	47 Neutral	$440.72M	―	-43.71%	―	―	80.95%
DMAC	42 Neutral	$474.95M	―	-64.12%	―	―	-29.73%
CTNM	39 Underperform	$306.67M	-4.61	-30.40%	―	―	-100.71%
TVRD	37 Underperform	$41.17M	-0.25	-97.61%	―	-53.67%	86.75%

Autolus Therapeutics Corporate Events

Autolus Therapeutics Reports Q3 2025 Financial Results

Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company specializing in the development, manufacturing, and delivery of next-generation programmed T cell therapies for cancer and autoimmune diseases. The company is known for its innovative approach in engineering targeted T cell therapies to improve clinical outcomes.

Autolus Therapeutics’ Earnings Call: Mixed Sentiments

Autolus Therapeutics has reported a mixed sentiment in its latest earnings call, reflecting both significant achievements and notable challenges. The successful launch of Obe-cel in the U.S. has been a highlight, with impressive market penetration and expansion into new clinical areas. However, financial challenges such as high cost of sales and increased operational losses present hurdles. Despite these challenges, the company remains well-capitalized to continue its growth and expansion strategies.

Autolus Therapeutics Appoints New Principal Accounting Officer

On November 7, 2025, Autolus Therapeutics announced the resignation of Rob Dolski as Principal Accounting Officer, with Patrick McIlvenny appointed to the role effective the same day. The company reported third-quarter 2025 financial results, including $21.1 million in net product revenue for AUCATZYL® and 60 authorized treatment centers. Autolus is advancing its obe-cel therapy for pediatric r/r B-ALL and severe lupus nephritis, with promising clinical data and FDA designations supporting further trials. Leadership changes aim to bolster commercial growth and operational efficiency.

The most recent analyst rating on (AUTL) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.

Autolus Therapeutics’ Earnings Call Highlights Growth and Challenges

The recent earnings call for Autolus Therapeutics highlighted a strong launch and positive reception of their product Obe-cel in the US, alongside significant progress in regulatory approvals and treatment center expansion. However, the company faces challenges with high costs, operational losses, delayed cash receipts, and market access difficulties in Europe.